Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Under The Radar: Bankruptcy News You May Have Missed No Photo Available

Yun Park

A creditor of bankrupt event venue The Chariot objected to the company's disclosure statement, saying it lacks details on how the cred... (more story)

Meet The Attorneys Laying Down Mosaic Co.'s Ch. 11 No Photo Available

Clara Geoghegan

Mosaic Companies, which owns several high-end tile and stone businesses, has filed for bankruptcy in Delaware to sell its assets and r... (more story)

Tariffs Loom Large Over Smaller Ch. 11s So Far In 2025 No Photo Available

Ben Zigterman

Mid-market businesses have been struggling with economic uncertainty in the first half of the year, especially with the threat of high... (more story)